Insider · CIK 0001219042
NELSEN ROBERT
Reports to the SEC for 52 companies · CAMBRIDGE, MA
Transactions
50
Companies
52
Filings
10
CIK
0001219042
Forms 4 and 5
Insider transactions
| Date | Company | Value |
|---|---|---|
| 2026-10-19 | CTYCITY THERAPEUTICS, INC.C Conversion | — |
| 2026-10-19 | CTYCITY THERAPEUTICS, INC.C Conversion | — |
| 2026-10-19 | CTYCITY THERAPEUTICS, INC.C Conversion | — |
| 2026-10-19 | CTYCITY THERAPEUTICS, INC.P Purchase | +$3.06M |
| 2026-10-19 | CTYCITY THERAPEUTICS, INC. · Series Seed convertible preferred stockC Conversion | — |
| 2026-10-19 | CTYCITY THERAPEUTICS, INC. · Series A convertible preferred stockC Conversion | — |
| 2026-10-19 | CTYCITY THERAPEUTICS, INC. · Series B convertible preferred stockC Conversion | — |
| 2026-10-15 | CTYCITY THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award | — |
| 2026-06-05 | PRMEPrime Medicine, Inc. · Stock Option (right to buy)A Award | — |
| 2026-06-04 | SANASana Biotechnology, Inc. · Stock Option (Right to Buy)A Award | — |
| 2025-08-01 | PRMEPrime Medicine, Inc.P Purchase | +$10M |
| 2025-08-01 | PRMEPrime Medicine, Inc. · Stock Option (right to buy)D Disposition to Issuer | — |
| 2025-08-01 | PRMEPrime Medicine, Inc. · Stock Option (right to buy)A Award | — |
| 2025-08-01 | PRMEPrime Medicine, Inc. · Stock Option (right to buy)D Disposition to Issuer | — |
| 2025-08-01 | PRMEPrime Medicine, Inc. · Stock Option (right to buy)A Award | — |
| 2025-06-05 | SANASana Biotechnology, Inc. · Stock Option (Right to Buy)A Award | — |
| 2025-06-04 | PRMEPrime Medicine, Inc. · Stock Option (right to buy)A Award | — |
| 2024-06-14 | LYELLyell Immunopharma, Inc. · Option (right to buy)A Award | — |
| 2024-06-12 | PRMEPrime Medicine, Inc. · Stock Option (right to buy)A Award | — |
| 2024-06-06 | SANASana Biotechnology, Inc. · Stock Option (Right to Buy)A Award | — |
| 2024-06-06 | SANASana Biotechnology, Inc. · Stock Option (Right to Buy)A Award | — |
| 2024-05-30 | VIRVir Biotechnology, Inc.A Award | — |
| 2024-05-30 | VIRVir Biotechnology, Inc. · Stock Option (Right to Buy)A Award | — |
| 2024-02-15 | PRMEPrime Medicine, Inc.P Purchase | +$20M |
| 2024-02-08 | SANASana Biotechnology, Inc.P Purchase | +$2M |
| 2024-02-08 | SANASana Biotechnology, Inc.P Purchase | +$4M |
| 2024-02-08 | SANASana Biotechnology, Inc.P Purchase | +$4M |
| 2023-09-08 | LYELLyell Immunopharma, Inc. · Option (right to buy)A Award | — |
| 2023-06-16 | LYELLyell Immunopharma, Inc. · Option (right to buy)A Award | — |
| 2023-06-14 | PRMEPrime Medicine, Inc. · Stock Option (right to buy)A Award | — |
| 2023-06-08 | SANASana Biotechnology, Inc. · Stock Option (Right to Buy)A Award | — |
| 2023-05-22 | VIRVir Biotechnology, Inc.A Award | — |
| 2023-05-22 | VIRVir Biotechnology, Inc. · Stock Option (Right to Buy)A Award | — |
| 2023-01-05 | SANASana Biotechnology, Inc.A Award | — |
| 2022-10-24 | PRMEPrime Medicine, Inc.C Conversion | — |
| 2022-10-24 | PRMEPrime Medicine, Inc.C Conversion | — |
| 2022-10-24 | PRMEPrime Medicine, Inc.P Purchase | +$6.8M |
| 2022-10-24 | PRMEPrime Medicine, Inc.P Purchase | +$6.8M |
| 2022-10-24 | PRMEPrime Medicine, Inc.C Conversion | — |
| 2022-10-24 | PRMEPrime Medicine, Inc. · Series A Convertible Preferred StockC Conversion | — |
| 2022-10-24 | PRMEPrime Medicine, Inc. · Series A Convertible Preferred StockC Conversion | — |
| 2022-10-24 | PRMEPrime Medicine, Inc. · Series B Convertible Preferred StockC Conversion | — |
| 2022-10-24 | PRMEPrime Medicine, Inc. · Series B Convertible Preferred StockC Conversion | — |
| 2022-10-24 | PRMEPrime Medicine, Inc. · Series A Convertible Preferred StockC Conversion | — |
| 2022-10-05 | SANASana Biotechnology, Inc.A Award | — |
| 2022-09-06 | VIRVir Biotechnology, Inc.J Other | — |
| 2022-09-06 | VIRVir Biotechnology, Inc.J Other | — |
| 2022-09-06 | VIRVir Biotechnology, Inc.J Other | — |
| 2022-09-06 | VIRVir Biotechnology, Inc.J Other | — |
| 2022-09-02 | VIRVir Biotechnology, Inc.J Other | — |
Recent filings
- 4NELSEN ROBERT0001104659-26-116965SEC(opens sec.gov)
- 4NELSEN ROBERT0001628280-26-041572SEC(opens sec.gov)
- 4NELSEN ROBERT0001770121-26-000003SEC(opens sec.gov)
- 4NELSEN ROBERT0001894562-25-000049SEC(opens sec.gov)
- 4NELSEN ROBERT0001062993-25-013462SEC(opens sec.gov)
- 4NELSEN ROBERT0001562180-25-004642SEC(opens sec.gov)
- 4NELSEN ROBERT0001628280-25-029772SEC(opens sec.gov)
- 4/ANELSEN ROBERT0001562180-24-005722SEC(opens sec.gov)
- 4NELSEN ROBERT0001415889-24-017220SEC(opens sec.gov)
- 4NELSEN ROBERT0001894562-24-000039SEC(opens sec.gov)
Companies
- 908 Devices Inc.10% OwnerMASS
- Achaogen, Inc.10% Owner
- ADESTO TECHNOLOGIES Corp10% Owner
- ADOLOR CORPDirector
- AGIOS PHARMACEUTICALS, INC.DirectorAGIO
- ALNYLAM PHARMACEUTICALS, INC.10% OwnerALNY
- Beam Therapeutics Inc.10% OwnerBEAM
- Bellerophon Therapeutics, Inc.Director, 10% Owner
- Bio Green Med Solution, Inc.Director, 10% OwnerBGMS
- bluebird bio, Inc.10% Owner
- Boundless Bio, Inc.10% OwnerBOLD
- CELEBRATE EXPRESS, INC.10% Owner
- CITY THERAPEUTICS, INC.Director, 10% OwnerCTY
- Codiak BioSciences, Inc.10% Owner
- DA32 Life Science Tech Acquisition Corp.10% Owner
- Denali Therapeutics Inc.DirectorDNLI
- Erasca, Inc.10% OwnerERAS
- FATE THERAPEUTICS INCDirector, 10% OwnerFATE
- Gossamer Bio, Inc.10% OwnerGOSS
- ILLUMINA, INC.Director, 10% OwnerILMN
- IMPINJ INC10% OwnerPI
- Juno Therapeutics, Inc.Director
- Kardigan, Inc.Director, 10% OwnerKARD
- Karuna Therapeutics, Inc.Director, 10% Owner
- KYTHERA BIOPHARMACEUTICALS INCFormer Director
- Lyell Immunopharma, Inc.10% OwnerLYEL
- Maze Therapeutics, Inc.10% OwnerMAZE
- Metacrine, Inc.10% Owner
- Metsera, Inc.Director, 10% OwnerMTSR
- Neumora Therapeutics, Inc.10% OwnerNMRA
- NeurogesX IncDirector, 10% Owner
- PHASERX, INC.10% Owner
- Prime Medicine, Inc.Director, 10% OwnerPRME
- Pulmatrix, Inc.Former 10% ownerPULM
- Q32 Bio Inc.10% OwnerQTTB
- Quanterix Corp10% OwnerQTRX
- Rapport Therapeutics, Inc.10% OwnerRAPP
- Receptos, Inc.10% Owner
- Revolution Healthcare Acquisition Corp.Director
- Sage Therapeutics, Inc.Director
- Sana Biotechnology, Inc.Director, 10% OwnerSANA
- Scholar Rock Holding Corp10% OwnerSRRK
- Seaport Therapeutics, Inc.10% OwnerSPTX
- Sienna Biopharmaceuticals, Inc.10% Owner
- Syros Pharmaceuticals, Inc.10% Owner
- Trubion Pharmaceuticals, Inc10% Owner
- Twist Bioscience Corp10% OwnerTWST
- Unity Biotechnology, Inc.Director
- VBI VACCINES INC.10% Owner
- Verve Therapeutics, Inc.10% Owner
- Vir Biotechnology, Inc.DirectorVIR
- XTERA COMMUNICATIONS, INC.10% Owner
Address
399 BINNEY STREET
CAMBRIDGE, MA, 02142